

## Nirmatrelvir/Ritonavir (Paxlovid®)

- What is it?**
- The combination of two medications, nirmatrelvir and ritonavir, taken together to treat individuals with non-severe COVID-19.
  - Nirmatrelvir is a SARS-CoV-2 protease inhibitor that works to disrupt viral replication. Ritonavir acts as a “pharmacokinetic booster” to inhibit nirmatrelvir hepatic metabolism and optimize nirmatrelvir plasma concentrations and dosing profile.



On January 17, 2022 nirmatrelvir/ritonavir was authorized for use by Health Canada via a Notice of Compliance with Terms and Conditions. The recommended treatment course of nirmatrelvir/ritonavir is 300 mg/100 mg po BID x 5 days.

**Health Canada  
Indication:**

**Treatment of mild-to-moderate COVID-19 in adults with a positive COVID-19 test result, and who are at high risk\* for progression to severe COVID-19, including hospitalization or death.**

\*High risk criteria may include:

- Older age (i.e., 60 years of age and older)
- Obesity or being overweight (i.e., BMI >25 kg/m<sup>2</sup>)
- Current cigarette smoking
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Active cancer
- Chronic lung disease (i.e., chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (i.e., cerebral palsy, Down’s syndrome) or other conditions that confer medical complexity (i.e., genetic or metabolic syndromes and severe congenital anomalies)
- Medical-related technological dependence not related to COVID-19 (i.e., tracheostomy, gastrostomy, or positive pressure ventilation)

*Note: Other medical conditions or factors (e.g., race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and may be considered on a case-by-case basis.*



### Evidence:

- Support comes from EPIC-HR, a Phase 2/3 RCT that enrolled 2246, unvaccinated, non-hospitalized adults ≥ 18 years of age with COVID-19 who were at high-risk\* for disease progression, between July 16 and December 9, 2021. Those eligible had no prior history of COVID-19 infection and an oxygen saturation of >92% on room air. Patients were randomized **within 5 days of symptom onset and positive SARS-CoV-2 test** to receive either 1) nirmatrelvir/ritonavir 300 mg/100mg po BID x 5 days or 2) placebo po BID x 5 days.<sup>1-2</sup> Key results are below.
- Data released from the manufacturer for EPIC-SR, a Phase 2/3 RCT including those at standard risk for developing severe COVID-19, suggests no difference in time to symptom alleviation, hospitalization, or death.<sup>3</sup>
- Several observational retrospective cohort studies demonstrate benefit of nirmatrelvir/ritonavir during circulation of the Omicron variant in mainly vaccinated, non-hospitalized adults with COVID-19 at high risk\* for progression.<sup>4-5</sup> In one study, those ≥ 65 years of age had lower rates of hospitalization (HR 0.27, 95% CI 0.05-0.82) and death (HR 0.21, 95% CI 0.05-0.82), and no evidence of benefit was found in those 40-64 years old.<sup>6</sup>
- A retrospective analysis in Hong Kong demonstrated lower all-cause mortality in 40776 adults (mainly >65 years old) hospitalized with mild-moderate COVID-19 (HR 0.32, 95% CI 0.23-0.45), between February and April, 2022.<sup>7</sup>
- There is a lack of evidence to suggest COVID-19 rebound between days 2 to 8 after initial recovery warrants additional treatment with nirmatrelvir/ritonavir<sup>8-9</sup>, or that susceptibilities of Omicron to nirmatrelvir/ritonavir are reduced.<sup>10</sup>

### EPIC-HR: double-blind, multicenter RCT, intention to treat analysis<sup>2</sup>

- **Fewer COVID-19-related hospitalizations and deaths by day 28:** 0.77% (8/1039) in nirmatrelvir/ritonavir group vs 6.31% (66/1046) in placebo; Absolute risk reduction (ARR) -5.62% (95% CI -7.21 to -4.03), p<0.001
  - 0 deaths in nirmatrelvir/ritonavir group vs 12 deaths in placebo
  - In those treated ≤ 3 days after symptom onset: 0.72% (5/697) vs 6.45% (44/682), ARR 5.81% (95% CI -7.78 to -3.84), p<0.001
- **Adverse events:** 22.6% in nirmatrelvir/ritonavir group vs 23.9% in placebo. Mainly dysgeusia (5.6% vs 0.3%) and diarrhea (3.1% vs 1.6%)

**Number needed to treat (NNT):** For every 17 COVID-19 outpatients who receive a 5-day course of nirmatrelvir/ritonavir, one fewer COVID-19-related hospitalization or death will occur by day 28 days versus placebo.

The Infectious Diseases Society of America (IDSA): suggests using nirmatrelvir/ritonavir within 5 days of symptom onset in ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease.<sup>11</sup>

### Practical Considerations



- Many clinically significant drug-drug interactions exist through the impact of ritonavir on hepatic cytochrome P450 enzymes. Pharmacist assessment and management is crucial.
- Requires dose adjustment for impaired renal function (eGFR < 60 mL/min).
- Supplied pre-packaged as a box containing 5 daily blister cards (reflecting standard dosing with a morning and an evening dose of 2x nirmatrelvir 150 mg tablets and 1x ritonavir 100 mg tablet).

## References:

1. Paxlovid product monograph. Kirkland (QC): Pfizer Canada ULC; Accessed 4 Nov 2022.
2. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med*. 2022 Apr 14;386(15):1397-1408.
3. Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA. Tuesday, June 14, 2022. Available at <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting>. Accessed 4 Nov 2022.
4. Ganatra S, Dani SS, Ahmad J, Kumar A, Shah J, Abraham GM, McQuillen DP, Wachter RM, Sax PE. Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19. *Clin Infect Dis*. 2022 Aug 20.
5. Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes I, Patel R, Gainer L, Dutton L, Donahue E, Gandhi RT, Baden LR, Woolley AE. Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system. *medRxiv [Preprint]*. 2022 Jun 17:2022.06.14.22276393.
6. Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, Friger M, Waxman JG, Dagan N, Balicer R, Ben-Shlomo Y, Peretz A, Yaron S, Serby D, Hammerman A, Netzer D. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. *N Engl J Med*. 2022 Sep 1;387(9):790-798.
7. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. *Lancet*. 2022 Oct 8;400(10359):1213-1222.
8. Boucau J, Uddin R, Marino C, Regan J, Flynn JP, Choudhary MC, Chen G, Stuckwisch AM, Mathews J, Liew MY, Singh A, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Turbett SE, Li JZ, Lemieux JE, Barczak AK, Siedner MJ. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. *Clin Infect Dis*. 2022 Jun 23.
9. Anderson AS, Caubel P, Rusnak JM; EPIC-HR Trial Investigators. Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19. *N Engl J Med*. 2022 Sep 15;387(11):1047-1049.
10. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. *N Engl J Med*. 2022 Apr 14.
11. Bhimraj A, Morgan RL, Shumaker AH, Baden L, Cheng VC, Edwards KM, Gallagher JC, Gandhi RT, Muller WJ, Nakamura MM, O'Horo JC, Shafer RW, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America 2022; Version 10.0.0. Available at <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>. Accessed 8 Nov 2022.